Amyris, Inc. (NASDAQ:AMRS) is scheduled to be announcing its earnings results after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.35). The firm had revenue of $25.68 million for the quarter, compared to analyst estimates of $23.68 million. During the same quarter last year, the business posted ($0.06) EPS. The firm’s revenue for the quarter was up 167.5% on a year-over-year basis. On average, analysts expect Amyris to post $-3.32 EPS for the current fiscal year and $-1.84 EPS for the next fiscal year.

Amyris, Inc. (AMRS) opened at 2.8894 on Tuesday. The stock’s 50 day moving average is $3.23 and its 200-day moving average is $4.08. Amyris, Inc. has a 52 week low of $1.86 and a 52 week high of $17.10. The firm’s market capitalization is $108.66 million.

TRADEMARK VIOLATION WARNING: “Amyris, Inc. (AMRS) Set to Announce Quarterly Earnings on Tuesday” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/24/amyris-inc-amrs-set-to-announce-quarterly-earnings-on-tuesday.html.

AMRS has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. HC Wainwright set a $15.00 price objective on shares of Amyris and gave the stock a “buy” rating in a report on Friday, August 11th. Cowen and Company set a $4.00 price objective on shares of Amyris and gave the stock a “hold” rating in a report on Thursday, August 17th. Finally, ValuEngine raised shares of Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $20.69.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.